Atopic Dermatitis

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

Latest News

Atopic dermatitis on hands | Image Credit: © Ольга Тернавская - stock.adobe.com
Yearly Flares in Atopic Dermatitis May Predict Disease Severity

August 20th 2025

In this study, total flares were investigated for their propensity to predict atopic dermatitis disease severity among adult patients.

Roflumilast cream | Image Credit: © luchschenF-stock.adobe.com
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients

August 15th 2025

atopic dermatitis | Image Credit: © wladimir1804-stock.adobe.com
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis

August 5th 2025

FDA approval | Image Credit: Maggie-sora.chatgpt.com
FDA Approves Delgocitinib for Moderate to Severe Hand Eczema

July 24th 2025

Atopic Dermatitis | Image Credit: Veranika-stock.adobe.com
Dupilumab Shows Strong Efficacy in SCORAD-Based AD Assessment

July 14th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives

More News

Rural land.
February 17th 2022

Jobs in Forestry, Agriculture Linked With Increased AD Risk in Workers' Children

Matthew Gavidia
Japanese children of parents whose family business was primarily industry, including agriculture, forestry, and fisheries, had a greater risk of atopic dermatitis (AD) development.
Child.
February 12th 2022

AD Severity Linked With Sleep, Attention Issues in Young Children

Matthew Gavidia
Children with moderate to severe atopic dermatitis were found to be more likely to report suboptimal sleep and attention regulation outcomes.
Robert Sidbury, MD, MPH.
February 11th 2022

Dr Robert Sidbury Explains Pathophysiology, Comorbidity Risk of Atopic Dermatitis

Matthew Gavidia
Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, speaks on the inflammatory mechanisms of atopic dermatitis and risk of comorbidities in affected patients.
FDA
February 3rd 2022

FDA Approves Abrocitinib for Adults With Moderate to Severe Atopic Dermatitis

Matthew Gavidia
The JAK1 inhibitor abrocitinib (Cibinqo) was recently approved by the FDA for the treatment of adults with refractory, moderate to severe atopic dermatitis.
Stethoscope.
January 31st 2022

Social Determinants May Influence Health Care Utilization, Symptom Burden in Patients With Asthma and Eczema

Matthew Gavidia
Minority patients and those with low income were more likely than White and high-income counterparts to report adverse outcomes in the management of asthma and eczema.
Flare.
January 29th 2022

Understanding, Managing Flares in Atopic Dermatitis

Matthew Gavidia
Researchers review current knowledge on the management of flares in atopic dermatitis, including treatment and unmet needs.
Health cross symbol.
January 27th 2022

Dupilumab Significantly Reduces Hospitalization Rates in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis (AD) treated with dupilumab showed reduced hospitalization rates and shorter duration of AD-related hospitalizations vs those treated with control therapies.
Health care cost.
January 21st 2022

Substantial Cost Burden, Health Care Utilization Found in Patients With Severe Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were associated with significant economic burden primarily driven by outpatient visits and pharmacy use, which increased with disease severity.
Physician, parent, and sick child.
January 19th 2022

Early-Life Infection Linked With Atopic Dermatitis Development in Infants, Children

Matthew Gavidia
Incidence of infectious diseases, skin infections, and systemic antibiotic exposure were all associated with the development of atopic dermatitis among infants and young children.
Spotlighting a patient.
January 13th 2022

Greater Risk of COVID-19 Infection Found in Patients With Atopic Dermatitis

Matthew Gavidia
Patients with atopic dermatitis were shown to be more likely to receive a COVID-19 diagnosis than the general population.
Child with mask.
January 11th 2022

Atopic Dermatitis Associated With Behavioral Issues in Children and Adolescents

Matthew Gavidia
Children and adolescents with atopic dermatitis (AD) tended to have a higher number of delinquent behaviors than those without AD, including fighting, cheating on exams, and suspension.
Person grasping hand.
January 6th 2022

Real-World Study Finds Dupilumab Safe, Effective for Moderate-to-Severe Atopic Dermatitis

Matthew Gavidia
Korean patients with moderate-to-severe atopic dermatitis achieved and maintained markedly improved skin clearance with dupilumab treatment in a real-world setting, including in the face and hands.
David R. Stukus, MD, FACAAI.
December 28th 2021

Dr David R. Stukus Spotlights Unmet Needs in Atopic Dermatitis Management

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.
Nurse and medical provider.
December 24th 2021

Evaluating Differences in Therapeutic, Diagnostic Approaches to Atopic Dermatitis

Matthew Gavidia
A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.
David R. Stukus, MD, FACAAI.
December 22nd 2021

Dr David R. Stukus Discusses Access, Affordability Concerns of Emerging Atopic Dermatitis Therapies

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the difficulties of gaining coverage for newer biologic therapies in the treatment of atopic dermatitis.
Happy child.
December 18th 2021

Dupilumab Shows High Effectiveness in AD for Ages 6 Months and Up

Matthew Gavidia
Research presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference said dupilumab (Dupixent) is an effective and safe therapeutic option in adults, adolescents aged 6 to 11 years, and young children aged 6 months to 5 years with moderate-to-severe atopic dermatitis.
David R. Stukus, MD, FACAAI.
December 17th 2021

Dr David R. Stukus on Immune-Related Response to Therapy in Atopic Dermatitis

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, discusses efforts to align novel treatments for atopic dermatitis with patients based on the underlying mechanisms of disease.
Many Questions Remain in Deciphering, Preventing Atopic March
December 14th 2021

Many Questions Remain in Deciphering, Preventing Atopic March

Jared Kaltwasser
In a new review article, investigators outline the challenges to studying the disease, but also point to big data as an important tool moving forward.
Person closing eye.
December 9th 2021

Patients With Atopic Dermatitis More Prone to Depression, Anxiety

Matthew Gavidia
Patients with atopic dermatitis, particularly those with more severe skin manifestations, were shown to be at greater risk of depression and anxiety compared with the general population.
Child in a hospital bed.
December 7th 2021

Increased Risk of Fracture Found in Children With Atopic Dermatitis

Matthew Gavidia
Children with atopic dermatitis were shown to be at an increased risk of fractures compared with the general population, with systemic use of corticosteroid and antihistamine therapy cited as mediating factors.
Patient and physician.
December 3rd 2021

Higher Risk of Systemic, Psychiatric Conditions Found in Patients With Atopic Dermatitis

Matthew Gavidia
A high comorbidity burden, including psychiatric, autoimmune, and systemic conditions, was found in US adult ambulatory populations with atopic dermatitis.
Doctor looking at electronic medical record.
December 1st 2021

Dupilumab-Induced Ophthalmic Disease Common in Adults With Atopic Dermatitis

Matthew Gavidia
More than 1 in 3 patients with atopic dermatitis reported incidence of dupilumab-induced ocular surface disease (DIOSD), with asthma and family history of AD shown to further increase the risk of developing DIOSD.
Human eye.
November 25th 2021

Atopic Dermatitis Severity, Age at Diagnosis May Increase Risk of Ophthalmic Diseases

Matthew Gavidia
Moderate-to-severe disease, childhood onset, and systemic treatments were all associated with a greater risk of conjunctivitis in patients with atopic dermatitis, whereas use of soft and hard contact lenses were linked with risk of keratitis.
Physician on a computer.
November 23rd 2021

Machine Learning Approach Finds Several Severity-Associated Factors in Atopic Dermatitis

Matthew Gavidia
Findings of a machine learning-based deep phenotyping approach found a myriad of factors associated with severe disease in atopic dermatitis, including age between 12 and 21 years or older than 52 years, lack of physical activity, and incidence of alopecia areata.
Jonathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences.
November 17th 2021

Dr Jonathan Silverberg on Potential Benefits, Challenges of JAK Inhibitor Use in Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, explains efficacy and safety implications of JAK inhibitor use for atopic dermatitis.
Vaccination needle.
November 10th 2021

Flu Vaccine May Decrease Asthma Risk in Patients With Atopic Dermatitis

Matthew Gavidia
Adults with atopic dermatitis were shown to be at lower risk of developing asthma if they were vaccinated against influenza, particularly those who adhered to yearly shots.
onathan Silverberg, MD, PhD, MPH, George Washington University School of Medicine and Health Sciences
November 9th 2021

Dr Jonathan Silverberg Explains JAK/STAT Pathway Involvement in Atopic Dermatitis

Jonathan Silverberg, MD, PhD, MPH, associate professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences, discusses the involvement of the JAK/STAT pathway in the pathogenesis of atopic dermatitis.
Child with parent and physician.
November 4th 2021

Children With Atopic Dermatitis More Prone to Depression, Internalizing Behaviors

Matthew Gavidia
Children with severe atopic dermatitis were shown to be at nearly 2-fold greater risk of both depression and internalizing behaviors, with mild disease also associated with internalizing behaviors in those as young as 4 years of age.
Child in hospital bed.
November 1st 2021

Prenatal Exposure to Metals May Increase Risk of Atopic Dermatitis in Children

Matthew Gavidia
Prenatal exposure to inorganic arsenic and coexposure to inorganic arsenic and cadmium was found to increase risk of atopic dermatitis by up to 2.42-fold in young Taiwanese children.
Ruxolitinib Cream Approved for Short-term Treatment of Atopic Dermatitis
September 22nd 2021

Ruxolitinib Cream Approved for Short-term Treatment of Atopic Dermatitis

AJMC Staff
Ruxolitinib cream, to be sold under the name Opzelura, is the first topical Janus kinase inhibitor cream for the treatment of atopic dermatitis.
<1
...
345678>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo